Amgen Inc AMGN:NASDAQ (Common Stock)

LastDaily Change / % ChangeDividend YieldVolumeAvg Volume (10 day)
188.01 0.00   0.00%2.85%4,018,2352.7M
Market data is delayed by at least 15 minutes.
Summary chart showing the current equity's performance of over the past 1 days
  • Advanced Charts
  • Embed the above chart in your blog or website

    Customize, copy, and then paste the generated code into your website.

Previous close 1/17/2018

Latest News Headlines for Amgen Inc

FDA Approves Addition Of Overall Survival Data To KYPROLIS(R) (carfilzomib) Label

Our results may be affected by our ability to successfully market both new and existing products domestically and internationally, clinical and regulatory developments involving current and future products, sales growth of recently launched products, competition from other products including biosimilars, difficulties or delays in manufacturing our products and global economic conditions. In addition, sales of our products are affected by pricing pressure, political and public scrutiny and reimbursement policies imposed by third-party payers, including governments, private insurance plans and managed care providers and may be affected by regulatory, clinical and guideline developments and domestic and international trends toward managed care and healthcare cost containment. Furthermore, our research, testing, pricing, marketing and other operations are subject to extensive regulation by domestic and foreign government regulatory authorities. Our business may be impacted by government investigations, litigation and product liability claims. In addition, our business may be impacted by the adoption of new tax legislation or exposure to additional tax liabilities. If we fail to meet the compliance obligations in the corporate integrity agreement between us and the U.S. government, we could become subject to significant sanctions. Further, while we routinely obtain patents for our products and technology, the protection offered by our patents and patent applications may be challenged, invalidated or circumvented by our competitors, or we may fail to prevail in present and future intellectual property litigation. We perform a substantial amount of our commercial manufacturing activities at a few key manufacturing facilities, including in Puerto Rico, and also depend on third parties for a portion of our manufacturing activities, and limits on supply may constrain sales of certain of our current products and product candidate development. In addition, we compete wit

Overall Survival Analysis From KYPROLIS(R) (Carfilzomib) Phase 3 ASPIRE Trial Published in the Journal of Clinical Oncology

This news release contains forward-looking statements that are based on the current expectations and beliefs of Amgen. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including estimates of revenues, operating margins, capital expenditures, cash, other financial metrics, expected legal, arbitration, political, regulatory or clinical results or practices, customer and prescriber patterns or practices, reimbursement activities and outcomes and other such estimates and results. Forward-looking statements involve significant risks and uncertainties, including those discussed below and more fully described in the Securities and Exchange Commission reports filed by Amgen, including our most recent annual report on Form 10-K and any subsequent periodic reports on Form 10-Q and Form 8-K. Unless otherwise noted, Amgen is providing this information as of the date of this news release and does not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise.

View more recent headlines

Peers Information HelpAMGN Amgen Inc vs. Peers

AMGN
Amgen Inc
8.11%
Abbott Laboratories
3.36%
Eli Lilly and Co
2.07%
Novo Nordisk A/S (ADR)
5.11%
Bristol-Myers Squibb Co
0.93%
AMGN
Amgen Inc
2.81%
Abbott Laboratories
1.90%
Eli Lilly and Co
2.61%
Novo Nordisk A/S (ADR)
2.03%
Bristol-Myers Squibb Co
2.59%
0.00%
AMGN
Amgen Inc
0.00%
Abbott Laboratories
0.00%
Eli Lilly and Co
0.00%
Novo Nordisk A/S (ADR)
0.00%
Bristol-Myers Squibb Co
Compare these stocks

Latest Annual and Quarterly SEC Filings

More Filings
10-K

This report contains detailed information about the company's business finances and management.

10-Q

Quarterly reports contain financial statement, a discussion from management and a list of company events (stock splits, acquisitions, etc.)

Company Background

Amgen Inc. is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine). It focuses on human therapeutics for the treatment of serious illness in the areas of oncology/hematology, cardiovascular disease and neuroscience. Its product candidates in Phase III include Erenumab for episodic migraine, Aranesp for myelodysplastic syndromes, BLINCYTO for acute lymphoblastic leukemia and IMLYGIC for metastatic melanoma.

http://www.amgen.com

Loading...

collapse, right-facing arrow indicating collapsed view of sectionOverview

A table providing an overview of the stock
Bid | Size-- | --
Ask | Size-- | --
Price Open187.70
Previous Close188.01
Day High189.30
Day Low185.9001
52 Week High9/14/2017 | 191.0999
52 Week Low1/24/2017 | 150.375
% Off 52 Week High-1.62%
% Off 52 Week Low25.03%
Beta (5 Yr)1.44
Volatility Avg1/17/2018 | 17.34
10-Day Avg. Volume2,741,247
Market data is delayed by at least 15 minutes.

collapse, right-facing arrow indicating collapsed view of sectionFundamentals

A table providing the fundamentals of the stock
EPS (TTM)9/30/2017 | 11.07
P/E Ratio9/30/2017 | 17.0
Market CapLarge Cap | 136.48B
Shares Outstanding725.91M
Float724.8M

collapse, right-facing arrow indicating collapsed view of sectionDividends

A table providing information about the dividends of the stock
Dividend Yield2.85%
Ex-Date2/14/2018
Dividend Announcement12/12/2017
Date of Record2/15/2018
Payable$1.32 - QRTR
Payable Date3/8/2018

expand, down-facing arrow indicating expanded view of sectionShare Statistics

A table providing statistics about shares of the stock
Shares Short10.31M
Short Ratio3.1
Short % of Float1.42%
As of 12/15/2017
The performance data quoted represents past performance. Past performance does not guarantee future results. Current performance may be lower or higher than the performance quoted. Investment return and principal value of an investment will fluctuate and when redeemed, the investment may be worth more or less than their original cost.
The research, tools, and information provided will not include every security available to the public.